NASDAQ:FULC Fulcrum Therapeutics (FULC) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free FULC Stock Alerts $7.25 +0.41 (+5.99%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$6.85▼$7.2650-Day Range$6.84▼$12.0052-Week Range$2.43▼$13.70Volume597,170 shsAverage Volume498,295 shsMarket Capitalization$449.07 millionP/E RatioN/ADividend YieldN/APrice Target$13.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Fulcrum Therapeutics alerts: Email Address Fulcrum Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside81.6% Upside$13.17 Price TargetShort InterestHealthy3.65% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 2 Articles This WeekInsider TradingSelling Shares$57,240 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.76) to ($1.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.01 out of 5 starsMedical Sector353rd out of 910 stocksPharmaceutical Preparations Industry156th out of 424 stocks 3.4 Analyst's Opinion Consensus RatingFulcrum Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageFulcrum Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.65% of the outstanding shares of Fulcrum Therapeutics have been sold short.Short Interest Ratio / Days to CoverFulcrum Therapeutics has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fulcrum Therapeutics has recently decreased by 5.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFulcrum Therapeutics does not currently pay a dividend.Dividend GrowthFulcrum Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FULC. Previous Next 2.0 News and Social Media Coverage News SentimentFulcrum Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Fulcrum Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for FULC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fulcrum Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $57,240.00 in company stock.Percentage Held by InsidersOnly 2.50% of the stock of Fulcrum Therapeutics is held by insiders.Percentage Held by Institutions89.83% of the stock of Fulcrum Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fulcrum Therapeutics are expected to grow in the coming year, from ($1.76) to ($1.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fulcrum Therapeutics is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fulcrum Therapeutics is -4.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFulcrum Therapeutics has a P/B Ratio of 1.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Fulcrum Therapeutics Stock (NASDAQ:FULC)Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More FULC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FULC Stock News HeadlinesApril 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialMarch 28, 2024 | finance.yahoo.comFulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy SymposiumApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 22, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 19, 2024 | finance.yahoo.comFULC Apr 2024 9.000 putMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)March 18, 2024 | finanznachrichten.deFulcrum Therapeutics, Inc.: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerMarch 18, 2024 | msn.comFulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical OfficerApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 18, 2024 | globenewswire.comFulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerMarch 13, 2024 | tmcnet.comFulcrum Deepens Collaboration with Esri, Recognized as Bronze PartnerMarch 8, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 8, 2024 | msn.comFulcrum hits 52-week high as CEO buys sharesMarch 7, 2024 | finance.yahoo.comFULC Jun 2024 15.000 callMarch 7, 2024 | finance.yahoo.comCEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More StockMarch 5, 2024 | finance.yahoo.comFulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma ConferenceMarch 1, 2024 | markets.businessinsider.comStrong Buy Rating for Fulcrum Therapeutics Amidst Promising Clinical Progress and Financial StabilityFebruary 29, 2024 | seekingalpha.comFulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | markets.businessinsider.comDeep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)February 28, 2024 | finance.yahoo.comFulcrum Therapeutics Full Year 2023 Earnings: Beats ExpectationsFebruary 28, 2024 | finance.yahoo.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call TranscriptFebruary 27, 2024 | globenewswire.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023February 26, 2024 | benzinga.comEarnings Preview: Fulcrum TherapeuticsFebruary 26, 2024 | markets.businessinsider.comFulcrum Therapeutics is about to announce its earnings — here's what to expectFebruary 22, 2024 | benzinga.comFulcrum Therapeutics Stock (NASDAQ:FULC), Short Interest ReportFebruary 20, 2024 | finance.yahoo.comFulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ETFebruary 20, 2024 | globenewswire.comFulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ETSee More Headlines Receive FULC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/22/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FULC CUSIPN/A CIK1680581 Webwww.fulcrumtx.com Phone(617) 651-8851FaxN/AEmployees76Year FoundedN/APrice Target and Rating Average Stock Price Target$13.17 High Stock Price Target$17.00 Low Stock Price Target$6.00 Potential Upside/Downside+81.6%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-97,330,000.00 Net Margins-3,470.05% Pretax Margin-3,470.05% Return on Equity-36.65% Return on Assets-33.62% Debt Debt-to-Equity RatioN/A Current Ratio17.71 Quick Ratio17.71 Sales & Book Value Annual Sales$2.81 million Price / Sales159.81 Cash FlowN/A Price / Cash FlowN/A Book Value$3.80 per share Price / Book1.91Miscellaneous Outstanding Shares61,940,000Free Float60,387,000Market Cap$449.07 million OptionableOptionable Beta2.29 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Alexander C. Sapir (Age 57)CEO, President & Director Dr. Bradley E. Bernstein M.D.Ph.D., FounderDr. Michael R. GreenFounderDr. Rudolf Jaenisch M.D.Ph.D., FounderDr. Tsun-Huei Lee M.D. (Age 60)Ph.D., Founder Dr. Danny ReinbergFounderMr. Alan A. Musso C.M.A. (Age 62)CPA, Chief Financial Officer Mr. Gregory TourangeauController & Principal Accounting OfficerDr. Jeffrey W. Jacobs Ph.D. (Age 61)Chief Scientific Officer Mr. Curtis G. Oltmans J.D. (Age 61)Senior VP, Chief Legal Officer & Corporate Secretary Comp: $83.98kMore ExecutivesKey CompetitorsAvid BioservicesNASDAQ:CDMOAnnexonNASDAQ:ANNXMersana TherapeuticsNASDAQ:MRSNLarimar TherapeuticsNASDAQ:LRMRNeurogeneNASDAQ:NGNEView All CompetitorsInsiders & InstitutionsDenali Advisors LLCSold 30,700 shares on 4/19/2024Ownership: 0.044%Mass General Brigham IncBought 205,356 shares on 4/4/2024Ownership: 0.332%Greg TourangeauSold 4,884 sharesTotal: $57,240.48 ($11.72/share)Opaleye Management Inc.Bought 130,000 shares on 2/15/2024Ownership: 0.210%RTW Investments LPSold 348,848 shares on 2/14/2024Ownership: 8.848%View All Insider TransactionsView All Institutional Transactions FULC Stock Analysis - Frequently Asked Questions Should I buy or sell Fulcrum Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" FULC shares. View FULC analyst ratings or view top-rated stocks. What is Fulcrum Therapeutics' stock price target for 2024? 6 brokerages have issued 12-month target prices for Fulcrum Therapeutics' shares. Their FULC share price targets range from $6.00 to $17.00. On average, they anticipate the company's share price to reach $13.17 in the next twelve months. This suggests a possible upside of 81.6% from the stock's current price. View analysts price targets for FULC or view top-rated stocks among Wall Street analysts. How have FULC shares performed in 2024? Fulcrum Therapeutics' stock was trading at $6.75 at the beginning of 2024. Since then, FULC stock has increased by 7.4% and is now trading at $7.25. View the best growth stocks for 2024 here. Are investors shorting Fulcrum Therapeutics? Fulcrum Therapeutics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 2,260,000 shares, a decrease of 5.4% from the March 15th total of 2,390,000 shares. Based on an average daily trading volume, of 668,800 shares, the short-interest ratio is presently 3.4 days. View Fulcrum Therapeutics' Short Interest. When is Fulcrum Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our FULC earnings forecast. How were Fulcrum Therapeutics' earnings last quarter? Fulcrum Therapeutics, Inc. (NASDAQ:FULC) released its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.04. The company earned $0.87 million during the quarter, compared to analysts' expectations of $0.65 million. Fulcrum Therapeutics had a negative trailing twelve-month return on equity of 36.65% and a negative net margin of 3,470.05%. What ETFs hold Fulcrum Therapeutics' stock? ETFs with the largest weight of Fulcrum Therapeutics (NASDAQ:FULC) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Simplify Health Care ETF (PINK) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL). What other stocks do shareholders of Fulcrum Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO). When did Fulcrum Therapeutics IPO? Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering on Thursday, July 18th 2019. The company issued 4,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink served as the underwriters for the IPO. Who are Fulcrum Therapeutics' major shareholders? Fulcrum Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Mass General Brigham Inc (0.33%) and Denali Advisors LLC (0.04%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Greg Tourangeau, James A Geraghty, Peter G Thomson, Ra Capital Management, LP, Robert J Gould and Robert J Gould. View institutional ownership trends. How do I buy shares of Fulcrum Therapeutics? Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FULC) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
